Tag Archives: medicine and drugs

New Way Cells May Regulate Pain And Cancer Signals

 Luxembourg, November, 2026  Receptors “on the move” reveal a new way cells may regulate pain and  cancer signals 

LIH researchers uncover how functional cell receptors travel on extracellular vesicles,  opening new avenues for understanding disease mechanisms and developing future  therapies 

Researchers at the Luxembourg Institute of Health (LIH) have discovered that an important cell receptor can leave the cell on tiny membranous particles known as extracellular vesicles, while remaining able  to capture biological signals. Published in the prestigious international journal Nature Communications,  the study reveals a previously overlooked mechanism that could influence the availability of molecules  involved in pain, inflammation and cancer. The findings may ultimately inform the development of  more precise drugs targeting this receptor system. 

G protein-coupled receptors, or GPCRs, form one of the most important families of therapeutic targets,  with more than one-third of marketed medicines acting on them. These receptors are generally  understood to operate at the surface of the cells in which they are produced, although there is  increasing evidence that this may not always be the case.  

Using the atypical chemokine receptor ACKR3 as a model, the researchers demonstrated that  functional receptors can also be exported from cells on extracellular vesicles following stimulation by its ligands. These microscopic particles, naturally released by cells, transport proteins and other biological material within the body and contribute to communication between cells. 

“Our findings show that the activity of a receptor does not necessarily end at the boundary of the cell  that produces it,” explains Dr Andy Chevigné, co-leader of the Immuno-Pharmacology and  Interactomics group at the LIH Department of Infection and Immunity (DII) and one of the study’s  corresponding authors. “By travelling on extracellular vesicles, ACKR3 may continue to regulate  biological signals in the surrounding environment and potentially at more distant sites.” 

ACKR3 acts as a molecular “scavenger”: it captures chemokines, which guide immune-cell movement  and contribute to cancer progression, as well as naturally occurring opioid peptides involved in pain  regulation. The LIH team found that cells release vesicles carrying ACKR3 both under normal conditions  and in greater quantities when the receptor is stimulated by its ligands. Crucially, the receptor remains  functional on the surface of these vesicles. It can continue to bind chemokines and opioid peptides,  reducing their availability to activate other receptors. 

This suggests that extracellular vesicles may act as mobile regulators, controlling where and for how  long these signals remain active. The researchers observed the phenomenon across several cellular  models, including human platelets, cancer cell lines and cells obtained from patients with chronic  lymphocytic leukaemia (CLL). Experiments in a mouse tumour model also detected ACKR3-containing  vesicles at sites away from the original tumour, pointing to a possible role in communication over  greater distances within the body.

The discovery provides a new perspective on the biological functions of ACKR3, a receptor implicated  in cancer, cardiovascular conditions and the regulation of the opioid system. 

“In cancer, chemokine signals can help tumour cells grow, migrate and interact with their surrounding  environment. By changing the local availability of these signals, ACKR3-bearing vesicles could  potentially influence tumour behaviour. Their presence in samples from patients with chronic  lymphocytic leukaemia makes this mechanism particularly relevant for further investigation”, explain  Drs Jérôme Paggetti and Etienne Moussay, leaders of the Tumor Stroma Interactions (TSI) group at the  LIH Department of Cancer Research (DoCR) and among the key investigators of the study. 

“ACKR3 can also capture natural opioid peptides and thereby regulate their availability to conventional  opioid receptors. Understanding how receptor-bearing vesicles contribute to this process could offer  new insights into pain regulation and potentially support the longer-term search for alternative  therapeutic approaches”, concludes Dr Martyna Szpakowska, co-leader of the Immuno-Pharmacology  and Interactomics group. 

Although the findings remain at a fundamental and preclinical stage, they indicate that future drug  development may need to consider not only receptors located on cells but also those circulating on  extracellular vesicles. Further studies will be required to establish the importance of this mechanism  in patients and determine whether it could be targeted safely or used therapeutically.  

The study was published in November 2026 in the journal Nature Communications with the full title  “Chemokine and opioid peptide scavenging through constitutive and ligand-induced release of ACKR3- bearing extracellular vesicles”. 

Funding and collaborations 

The work was supported by LIH through the NanoLux Platform, the Luxembourg National Research  Fund (FNR) through several CORE, INTER, AFR and PRIDE grants, the Fondation Cancer Luxembourg,  F.R.S.-FNRS-Télévie and several European and international funding organisations. 

The study was led by the Immuno-Pharmacology and Interactomics group of the LIH Department of  Infection and Immunity (DII), in close collaboration with the Tumor Stroma Interactions group of the  LIH Department of Cancer Research (DoCR), with the particular contribution of researchers Christie  Palmer (DII), Lucie Rospape (DoCR) and Max Meyrath (DII). The research brought together scientists  from Luxembourg, Belgium, the Netherlands, Germany, the United Kingdom and Canada, including  partners at the Vrije Universiteit Amsterdam, the University of Amsterdam, Ghent University,  University Hospital Tübingen, McGill University, the University of Nottingham, University Hospital Jena  and Université de Montréal. It was also conducted within the framework of the European  ONCORNET2.0 network and of the CANBIO2 doctoral school. 

About the Luxembourg Institute of Health (LIH) 

The Luxembourg Institute of Health (LIH) is a public biomedical research organisation focused on precision health  and invested in becoming a leading reference in Europe for the translation of scientific excellence into meaningful  benefits for patients. 

The LIH places the patient at the heart of all its activities, driven by a collective obligation towards society to use  knowledge and technology arising from research on patient derived data to have a direct impact on people’s  health. Its dedicated teams of multidisciplinary researchers strive for excellence, generating relevant knowledge  linked to immune related diseases and cancer.

The institute embraces collaborations, disruptive technology and process innovation as unique opportunities to  improve the application of diagnostics and therapeutics with the long-term goal of preventing disease. 

Scientific contacts: 

Dr Andy Chevigné 

Group Leader, Immuno-Pharmacology and Interactomics 

Department of Infection and Immunity 

Luxembourg Institute of Health 

Email: Andy.Chevigne@lih.lu 

Dr Martyna Szpakowska 

Group Leader, Immuno-Pharmacology and Interactomics 

Department of Infection and Immunity 

Luxembourg Institute of Health 

Email: Martyna.Szpakowska@lih.lu 

Dr Jérôme Paggetti 

Group Leader, Tumour Stroma Interactions  

Department of Cancer Research  

Luxembourg Institute of Health 

For the Silo, Sabine Schmitz.  Head of Strategic Communications & External Relations , Luxembourg Institute of Health 

Featured image- Extra-cellular vessicle.

Artificial Stimulants In Energy Drinks Hurt Kids

Monster Energy Drink 666 Hebrew Numbers

Why Your Kid Shouldn’t Be Guzzling ‘Energy’ Drinks
Vitamins & Minerals are Safer and More Effective than
Artificial Stimulants, Says Food Science Expert

Anxiety, hypertension, elevated heart rates, interrupted sleep patterns and headaches are just some of the side effects commonly associated with energy drinks, and those problems are more pronounced in children, according to a recent University of Miami study.

But that’s just the tip of the iceberg. These drinks have also been linked to heart palpitations, strokes and sudden death.

The term “energy” drink is an unfortunate misnomer, says food science expert Budge Collinson. They don’t give your body energy; they stimulate you with brief jolts of caffeine and unregulated herbal stimulants, he says.

“Soccer moms and dads buy these ‘stimulant’ drinks for their kids before matches because both kids and parents want that competitive advantage,” says Collinson, founder of Infusion Sciences and creator of Youth Infusion, (www.drinkyouthinfusion.com), an effervescent, natural multivitamin beverage that helps people maintain consistent and healthy higher energy levels. 

“For a few moments, you’ll get that spike, but it’s a short-term experience with a heavy long-term toll.”

So, what are some ways kids can get a healthy energy boost? Collinson offers the following tips.

•  Go for a speedy bike ride together, take a brisk walk or hold foot-races in the yard. Numerous studies demonstrate the power of vigorous exercise in boosting energy. Exercise pumps more oxygen – pure, healthy fuel — into the bloodstream and to the brain and muscles for a short-term energy boost. Exercising regularly will increase lung capacity, so the body will gets more oxygen on a sustained level for the long term. Exercise also releases endorphins, the body’s natural feel-good chemical, which makes us feel happy. And happy people are energized people.

•  Seek nutrition from a variety of sources. As humans, we need more than 40 different vitamins and minerals to keep our bodies functioning optimally. Since there is no single food that contains them all, it is important for children and adults to eat a variety, including as many different vegetables and fruits as possible. Adding a daily multivitamin supplement with essentials such as CoQ10, arginine, theanine, resveratrol and magnesium can help ensure bodies young and old are running at top speed.

•  Drink plenty of water – the natural energy drink. Even mild dehydration can leave children (and adults) feeling listless, so encourage children to make a habit of drinking plenty of water. Kids need more water than adults because they expend more energy, and they may not recognize when they’re slightly thirsty. Parents, too, often don’t recognize the signs of dehydration; a national survey of more than 800 parents of kids ages of one month to 10 years found that more than half feel they don’t know enough about dehydration. A quick, light pinch of the skin on the child’s hand or arm is an easy check. If the skin is slow to resume a smooth appearance, the child is likely at least mildly dehydrated.

About Budge Collinson

Budge Collinson was the beneficiary of his mother’s natural health formula as a sick baby, which led to a deep interest in health and wellness at a young age. After years of research and seeing the growing demand for natural products with clinical support, he founded Infusion Sciences, www.infusionsciences.com. Collinson earned a bachelor’s degree in food and resource economics from the University of Florida and certification from the National Academy of Sports Medicine. Recently, he became a member of the American Academy of Anti-Aging Medicine and consistently attends the Natural Products Expo, where he learns the latest science and news about nutritious ingredients. Collinson is also a go-to source for media outlets across the country for healthy lifestyle and food source discussions.

Click to view on I-tunes
Click to view on I-tunes